Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 17

ACCELERATING THE DEVELOPMENT OF CURATIVE MEDICINES WITH FUNCTIONAL IMMUNE PROFILING
to compare the effects of two CAR-T cell lines (hYP7
and HN3) in mice with xenograft or orthoptic liver
tumors. Both CAR-T treatments targeted the tumor
antigen glypican 3 (GPC3), which is highly expressed
in hepatocellular carnicoma (HCC). The researchers
found that mice treated with the hYP7, but not the
HN3 CAR-T cells experienced reduced tumor burden
and persistent expansion of T cells and subsets of polyfunctional
CAR-T cells. There was a direct correlation
between pre-clinical outcome and presence of highly
polyfunctional CAR-T cells. Single-cell secretomics
revealed that GPC3-targeted hYP7 CAR-T cells inhibited
Wnt signaling and promoted apoptosis in tumor
cells. The researchers also found that polyfunctional
hYP7 CAR-T cells showed antigen-persistence and
expansion leading to tumor regression in HCC mouse
models, making hYP7 CAR-T products a potential
candidate for the treatment of liver cancer.8
Lastly, a study by Zhou et al., published in Human
Vaccines & Immunotherapeutics, used IsoPlexis'
immune profiling with a mouse model to evaluate
the efficacy of a novel malaria vaccine. IsoPlexis'
single-cell secreted proteomics analyzed the PfSPZ
anti-malaria vaccine and identified a subset of
polyfunctional hepatic CD8+ T cells in vaccinated
mice that were exposed to malaria. The researchers
analyzed the cytokines and chemokines secreted
by these polyfunctional cell subsets and identified
several which were associated with protective T
cell responses to diseases such as malaria.9
In these
studies and others, IsoPlexis' walk-away automated
platform generates insights quicker than traditional
animal models, helping to accelerate therapy
development and the path to human clinical trials,
where researchers can apply IsoPlexis' various panels
for human samples, enabling highly multiplexed
automation of the development and testing process
from start to finish. n
Roundtable:
Single-Cell
Proteomics Tackles
Vaccine Development
Download our roundtable with leading
researchers in infectious disease and vaccine
development to learn more about how singlecell
proteomics can help you develop better
vaccines and therapeutics.
DOWNLOAD
RESOURCE
1
CLT-0010
2
CLT-0011
3
CLT-0013
4
CLT-0122
5
CLT-0014
6
CLT-0126
7
CLT-0132
8
CLT-0018
isolight
GENengnews.com | 17
https://www.isoplexis.com/literature/roundtable-single-cell-proteomics-tackles-vaccine-development/#download http://www.GENengnews.com

Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines

Table of Contents for the Digital Edition of Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines

Contents
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 1
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 2
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - Contents
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 4
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 5
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 6
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 7
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 8
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 9
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 10
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 11
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 12
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 13
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 14
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 15
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 16
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 17
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 18
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 19
Isoplexis_July2021_AcceleratingDevelopmentCurativeMedicines - 20
https://www.nxtbookmedia.com